Novel mutations in transthyretin gene associated with hepatocellular carcinoma

被引:7
|
作者
Katare, Deepshikha P. [1 ]
Malik, Shabnam [2 ]
Mani, Ruchi J. [1 ]
Ranjpour, Maryam [2 ]
Jain, Swatantra K. [2 ,3 ]
机构
[1] Amity Univ, Amity Inst Biotechnol, Prote & Translat Res Lab, Ctr Med Biotechnol, Noida, Uttar Pradesh, India
[2] Hamdard Univ, Fac Chem & Life Sci, Dept Biotechnol, Hamdard Inst Med Sci & Res, New Delhi 110062, India
[3] Hamdard Univ, Dept Med Biochem, Hamdard Inst Med Sci & Res, New Delhi, India
关键词
2-aminoacetylfluorine; apolipoprotein A1; diethylnitrosamine; expression; mutations; tetramer formation; PROTEIN; SERUM; CANCER; IDENTIFICATION; SPECIFICITY; VARIANTS; BINDING; BIOMARKERS; RESIDUES;
D O I
10.1002/mc.22732
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatocellular carcinoma (HCC) is one of the major health problems with increasing incidence worldwide. We report the elevation in transthyretin (TTR) expression following HCC induction using diethylnitrosamine (DEN) and 2-aminoacetylfluorine (2-AAF) in male Wistar rats. The increase in its expression took place at very early stage and remained elevated throughout HCC progression. The analysis of TTR gene in HCC bearing rats revealed four novel mutations that alter three amino acids at positions 61, 100, and 115. While these mutations do not directly affect the binding of TTR to thyroxine (T-4), the mutation in amino acid 115 interferes with TTR tetramer formation that leads to its accumulation. Further, the mutated TTR is unable to cleave C-terminal of apolipoprotein A1 (APOA1) that results in abnormal lipid metabolism. This has correlation with development of liver cirrhosis and HCC. Furthermore, the mutated TTR seems to have potential as biomarker for early detection of HCC.
引用
收藏
页码:70 / 77
页数:8
相关论文
共 50 条
  • [1] DOUBLE-GENE MUTATIONS ASSOCIATED WITH SURVIVAL OF PATIENTS WITH HEPATOCELLULAR CARCINOMA
    Xing, Leng
    Song, Hui
    Diao, Shujing
    Zhan, Peng
    Li, Wenlan
    MEDICINE, 2023, 102 (03)
  • [2] The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
    Muller, Miryam
    Bird, Thomas G.
    Nault, Jean-Charles
    JOURNAL OF HEPATOLOGY, 2020, 72 (05) : 990 - 1002
  • [3] Mutations of the HFE gene and the risk of hepatocellular carcinoma
    Racchi, O
    Mangerini, R
    Rapezzi, D
    Gaetani, GF
    Nobile, MT
    Picciotto, A
    Ferraris, AM
    BLOOD CELLS MOLECULES AND DISEASES, 1999, 25 (22) : 350 - 353
  • [4] HFE gene mutations and risk of hepatocellular carcinoma
    Herruzo, J. A. Solis
    Munoz, P. Solis
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2007, 99 (07) : 369 - 375
  • [5] Mutations of the HFE gene in patients, with hepatocellular carcinoma
    Cauza, E
    Peck-Radosavljevic, M
    Ulrich-Pur, H
    Datz, C
    Gschwantler, M
    Schöniger-Hekele, M
    Hackl, F
    Polli, C
    Rasoul-Rockenschaub, S
    Müller, C
    Wrba, F
    Gangl, A
    Ferenci, P
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (02): : 442 - 447
  • [6] Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma
    Tannapfel, A
    Sommerer, F
    Benicke, M
    Katalinic, A
    Uhlmann, D
    Witzigmann, H
    Hauss, J
    Wittekind, C
    GUT, 2003, 52 (05) : 706 - 712
  • [7] HFE gene mutations in patients with hepatocellular carcinoma
    Hellerbrand, C
    Poeppl, A
    Hartmann, A
    Schoelmerich, J
    Lock, G
    HEPATOLOGY, 1999, 30 (04) : 583A - 583A
  • [8] Identification and characterization of a novel human hepatocellular carcinoma-associated gene
    Wang, ZX
    Wang, HY
    Wu, MC
    BRITISH JOURNAL OF CANCER, 2001, 85 (08) : 1162 - 1167
  • [9] Identification and characterization of a novel human hepatocellular carcinoma-associated gene
    Z-X Wang
    H-Y Wang
    M-C Wu
    British Journal of Cancer, 2001, 85 : 1162 - 1167
  • [10] Two novel mutations associated with transthyretin type amyloidosis (ATTR)
    Théberge, R
    Connors, L
    Skinner, M
    Skare, J
    Falk, R
    Costello, CE
    AMYLOID AND AMYLOIDOSIS 1998, 1999, : 300 - 302